Galapagos NV (FRA:GXE) Tax Provision : €4.3 Mil (TTM As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Tax Provision?

Galapagos NV's tax provision for the three months ended in Sep. 2024 was €0.6 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was €4.3 Mil.

Galapagos NV Tax Provision Historical Data

The historical data trend for Galapagos NV's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Tax Provision Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

0.17

-1.23

-1.39

-0.57

-9.61

Galapagos NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															0.57	2.55	0.57	0.57	0.57

Galapagos NV Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.3 Mil.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Galapagos NV Headlines

No Headlines